Literature DB >> 9029103

Anti-human kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide kappa R(33-52) derived from the predicted amino terminal region of the human kappa receptor.

R R Buchner1, S M Vogen, W Fischer, M L Thoman, S D Sanderson, E L Morgan.   

Abstract

Site-directed polyclonal Abs specific for a synthetic peptide with sequence homology to the predicted N-terminal sequence of the human kappa opioid receptor [anti-kappa R-(33-52)] are capable of binding to normal human cells and cell lines expressing mRNA specific for the human kappa receptor. Flow cytometric analysis of 1) a neuronal cell line (NT2), 2) blood-derived CD14+ monocytes, 3) monocyte-like cell lines (U937 and THP 1), 4) blood-derived CD3+ T cells and a T cell line, and 5) human B cell lines bound anti-kappa R-(33-52) in a specific manner. Anti-kappa R-(33-52) was also found to specifically neutralize the immunosuppressive activities associated with the kappa R-selective agonist U50,488H. This antiserum was found to block U50,488H-mediated inhibition of 1) Staphylococcus aureus Cowen strain I-induced B and T lymphocyte proliferation, 2) PHA-induced T lymphocyte proliferation, and 3) S. aureus Cowen strain I-induced IgG production. However, this antiserum failed to neutralize mu R-selective agonist (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol)-mediated suppression of IgG synthesis. Finally, the kappa R-selective antagonist nor-binaltorphimine hydrochloride inhibits the binding of anti-kappa R-(33-52) to the U937 cell line. These results suggest that anti-kappa R-(33-52) specifically interacts with the human kappa R molecule. Studies conducted with anti-kappa R-(33-52) indicated that this antiserum effectively blocked U50,488H-mediated immunosuppression, but by itself did not enhance or suppress lymphocyte activation. These data suggest that anti-kappa R-(33-52) 1) does not interact with the effector binding site of the receptor, but sterically interferes with U50,488H binding to the receptor; and/or 2) the antiserum interacts with a secondary binding site that is important for ligand binding, but may not be involved in signal transduction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029103

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

2.  Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Authors:  Bala Vamsi K Karuturi; Shailendra B Tallapaka; Joy A Phillips; Sam D Sanderson; Joseph A Vetro
Journal:  Clin Immunol       Date:  2015-06-23       Impact factor: 3.969

3.  Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.

Authors:  Joy A Phillips; Edward L Morgan; Yuxiang Dong; Garry T Cole; Cody McMahan; Chiung-Yu Hung; Sam D Sanderson
Journal:  Bioconjug Chem       Date:  2009-09-29       Impact factor: 4.774

4.  Dynorphin 1-17 and Its N-Terminal Biotransformation Fragments Modulate Lipopolysaccharide-Stimulated Nuclear Factor-kappa B Nuclear Translocation, Interleukin-1beta and Tumor Necrosis Factor-alpha in Differentiated THP-1 Cells.

Authors:  Siti Sarah Fazalul Rahiman; Michael Morgan; Paul Gray; Paul Nicholas Shaw; Peter John Cabot
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

5.  Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Authors:  Sam D Sanderson; Marilyn L Thoman; Kornelia Kis; Elizabeth L Virts; Edgar B Herrera; Stephanie Widmann; Homero Sepulveda; Joy A Phillips
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.